Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Trypan Blue Free Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 5/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.74 |
| ▸ | PHLPP2 | Q6ZVD8 | 2/20 | 0.63 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.60 |
| ▸ | ALB | P02768 | 1/20 | 0.55 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.55 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.55 |
| ▸ | TST | Q16762 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | GRK2 | P25098 | 1/20 | 0.53 |
| ▸ | PLEC | Q15149 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trypan Blue Free Acid SCHEMBL29350476 | 1.00 | PTPN1 (1.00) | PTPN1USP2ATML3MBTL1MEN1 | |
| Trypan Blue Free Acid SCHEMBL31686853 | 1.00 | PTPN1 (1.00) | PTPN1USP2ATML3MBTL1MEN1 | |
| Trypan Blue Free Acid SCHEMBL9724 | 1.00 | PTPN1 (1.00) | PTPN1USP2ATML3MBTL1MEN1 | |
| SCHEMBL29637809 | 0.91 | PTPN1 (0.83) | PTPN1USP2ATML3MBTL1MEN1 | |
| SCHEMBL29637844 | 0.90 | PTPN1 (0.81) | PTPN1USP2ATML3MBTL1MEN1 | |
| SCHEMBL29601587 | 0.88 | PTPN1 (0.79) | PTPN1USP2ATML3MBTL1MEN1 | |
| SCHEMBL29402157 | 0.88 | PTPN1 (0.79) | PTPN1USP2ATML3MBTL1MEN1 | |
| SCHEMBL20496488 | 0.88 | PTPN1 (0.79) | PTPN1USP2ATML3MBTL1MEN1 | |
| SCHEMBL9222420 | 0.87 | PTPN1 (0.77) | PTPN1USP2ATML3MBTL1MEN1 | |
| Trypan Blue Free Acid SCHEMBL15497820 | 0.85 | MEN1 (1.00) | PTPN1USP2ATML3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 466 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4076149-B1 | SYSTEM AND COMPUTER PROGRAM FOR IDENTIFYING BLOOD VESSELS DURING FLUORESCENCE IMAGING | PERFUSION TECH APS (DK) | 2025-12-24 | — | — | EP | claimed |
| EP-4114925-B1 | METHODS OF MANUFACTURING ACTIVATED IMMUNE CELLS | BIOECLIPSE THERAPEUTICS INC (US) | 2025-11-05 | — | — | EP | claimed |
| EP-2524338-B1 | CELL CHARACTERIZATION USING MULTIPLE FOCUS PLANES | BIO RAD LABORATORIES INC (US) | 2024-12-18 | — | — | EP | claimed |
| EP-3253420-B1 | METHODS AND SYSTEMS FOR CHARACTERIZING TISSUE OF A SUBJECT | STRYKER CORP (US) | 2024-11-20 | — | — | EP | claimed |
| EP-4433110-A1 | SUPPORTING MEMBRANE AND METHOD FOR PRODUCING A SUPPORTING MEMBRANE | Universität Rostock (DE) | 2024-09-25 | — | — | EP | claimed |
| EP-3188705-B1 | PHOTO-CHEMICALLY ACTIVATED MICRO-BUBBLE BASED ROOT CANAL DISINFECTION | SYACT INT LLC (US) | 2024-08-07 | — | — | EP | claimed |
| EP-3352670-B1 | METHOD AND SYSTEM FOR ASSESSING HEALING OF TISSUE | STRYKER EUROPEAN OPERATIONS LTD (IE) | 2024-05-08 | — | — | EP | claimed |
| EP-3402812-B1 | MODULATORS OF ZINC ACTIVATED CATION CHANNEL | DIGNITY HEALTH (US) | 2024-03-27 | — | — | EP | claimed |
| CN-114126201-B | PCB based on pulse VCP electroplating and preparation method thereof | 广德东风电子有限公司 | 2023-07-28 | — | — | CN | claimed |
| CN-114126244-B | PCB production method based on laser direct writing exposure | 广德东风电子有限公司 | 2023-07-14 | — | — | CN | claimed |
| WO-2023088729-A1 | SUPPORTING MEMBRANE AND METHOD FOR PRODUCING A SUPPORTING MEMBRANE | UNIVERSITÄT ROSTOCK (DE) | 2023-05-25 | — | — | WO | claimed |
| EP-3416658-B1 | HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF | KYOTO PREFECTURAL PUBLIC UNIV CORP (JP) | 2023-03-22 | — | — | EP | claimed |
| EP-3494791-B1 | TREATMENT OF SKIN-RELATED SYMPTOMS OF EHLERS-DANLOS SYNDROME WITH POLY-N-ACETYLGLUCOSAMINE NANOFIBERS | MARINE POLYMER TECH INC (US) | 2023-03-01 | — | — | EP | claimed |
| EP-4746906-A1 | IMMUNOGENIC COMPOSITIONS CONTAINING INACTIVATED INFLUENZA A VIRUS AND CPG OLIGONUCLEOTIDE ADJUVANT AND USES THEREOF | Icahn School of Medicine at Mount Sinai (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4748439-A2 | A PEPTOID-PEPTIDE HYBRID, NMEG-ALPHA-CGRP, AND ITS USE IN CARDIOVASCULAR DISEASES | University of South Carolina (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4748447-A2 | INFLUENZA VIRUS VACCINES AND USES THEREOF | Icahn School of Medicine at Mount Sinai (US) | 2026-05-27 | — | — | EP | disclosed |
| US-11241402-B2 | Methods of treating liver fibrosis by administering 3-bromopyruvate | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-02-08 | — | — | US | disclosed |
| US-11241458-B2 | Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo | REGENLAB USA LLC (US) | 2022-02-08 | — | — | US | disclosed |
| US-20220031710-A1 | USE OF ERK5 INHIBITORS FOR TREATING GLIOMAS IN PEDIATRIC SUBJECTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-02-03 | — | — | US | disclosed |
| US-20220031860-A1 | ANTIBODIES MODIFIED FOR TRANSGLUTAMINASE CONJUGATION, CONJUGATES THEREOF, AND METHODS AND USES | BRISTOL-MYERS SQUIBB COMPANY | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11241402-B2 | Methods of treating liver fibrosis by administering 3-bromopyruvate | PYGL, PLPBP, FIBP | THRB 2210/4885PTPN1 3277/4885USP2 2506/4885 |
| US-20220031860-A1 | ANTIBODIES MODIFIED FOR TRANSGLUTAMINASE CONJUGATION, CONJUGATES THEREOF, AND METHODS AND USES | TGM2, TGM1, TGM3 | THRB 1214/4885PTPN1 4499/4885USP2 1127/4885 |
| US-20220031710-A1 | USE OF ERK5 INHIBITORS FOR TREATING GLIOMAS IN PEDIATRIC SUBJECTS | DOT1L, IQGAP1, EZH2 | THRB 2443/4885PTPN1 1822/4885USP2 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.